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Abstract: In unmodified synaptosomal brain membranes 
the presence of NaCl inhibited the binding to p receptors 
of the tritiated opioid agonists etorphine, Tyr-D-Ala-Gly- 
(Me)Phe-Gly-ol, and sufentanil by 53,43, and 37%. respec- 
tively, and increased that of the antagonist [3H]naltrexone 
by 54%. On the other hand, in membranes whose microvis- 
cosity was increased by incorporation of cholesteryl hemi- 
succinate (CHS) the effects of sodium on opioid agonist 
and antagonist binding were abolished and strongly re- 
duced, respectively. Furthermore, in the modified mem- 
branes the ability of sodium to protect the opioid receptor 
from inactivation by the sulfhydryl-reactive agent N-ethyl- 
maleimide (NEM) was diminished. In CHS-treated mem- 
branes whose elevated microviscosity was reduced by the 
incorporation of oleic acid, the effectiveness of sodium in 
modulating opioid binding and attenuating receptor inacti- 
vation by NEM was restored. The results implicate mem- 
brane microviscosity in the mechanism by which sodium 
modulates the conversion between agonist- and antago- 
nist-favoring states of p opioid receptor. Key Words: Rat 
brain cortex-Fluorescence polarization-Membrane flu- 
idity-Opioid agonists and antagonists-Cholesterol- 
Fatty acids. 
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The function of intrinsic membrane proteins has 
been shown to depend on the lipid bilayer within 
which they reside. This modulation either occurs as a 
result of specific lipid-protein interactions (Tefft et 
al., 1986) or involves changes in the bulk physical 
properties of the membrane such as microviscosity 
(Swann, 1984). Specifically, altered membrane lipid 
composition (Fong and MacNamee, 1987) or mem- 
brane microviscosity (Zhang and Yang, 1989) has af- 
fected the conformation of membrane proteins. 
There is ample evidence for the sensitivity of opioid 
receptor function to lipids: Reconstitution expen- 
ments with partially purified receptor have demon- 
strated a requirement for specific lipids to support 
high-affinity opioid binding (Hasegawa et al., 1987), 
and ligand interaction with opioid receptors in brain 
was strongly influenced by the fluidity of the mem- 
brane environment (Remmers et al., 1990; Lazar and 
Medzihradsky, 1992). 
Based on (a) the ability of sodium to enhance 
opioid antagonist binding while reducing that of ago- 
nist (Pert et al., 1973), (b) the distinct inhibition of 
opioid agonists and antagonists binding by protein- 
modifying reagents (Pasternak et al., 1975), and (c) 
protection by sodium of receptor inactivation by the 
sulfhydryl-reactive agent N-ethylmaleimide (NEM) 
(Simon and Groth, 1975), a two-state model for 
opioid receptor was forwarded in which sodium in- 
duces the conversion of the receptor from an “ago- 
nist” to an “antagonist” conformation (Pasternak 
and Snyder, 1975; Simon and Groth, 1975; Simon 
and Hiller, 198 1). Considering the evidence for a role 
of membrane fluidity in the conformational transi- 
tion of proteins and in the modulation of opioid re- 
ceptor binding, we have in this study examined the 
sodium-induced conversion between the agonist- and 
antagonist-favoring states of opioid receptor in brain 
membranes with altered microviscosity. 
MATERIALS AND METHODS 
Materials 
[3H]Etorphine (specific activity, 40 Ci/mmol) and 
[3H]Tyr-~-Ala-Gly-(Me)Phe-Gly-ol ( [3H]DAMGO; specific 
activity, 60 Ci/mmol) were purchased from Amersham Co., 
whereas [3H]sufentanil (specific activity, 54 Ci/mmol) and 
[3H]naltrexone (specific activity, 22 Ci/mmol) were ob- 
tained from Janssen Life Sciences Products and the Na- 
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tional Institute on Drug Abuse, respectively. All unlabeled 
opioids were supplied by the Narcotic Drug and Opiate Pep- 
tide Basic Research Center at the University of Michigan. 
Cholesteryl hemisuccinate (CHS), cis-9-octadecenoic acid 
[oleic acid (OA)], NEM, and dithiothreitol were obtained 
from Sigma Chemical Co., whereas diphenylhexatriene 
(DPH) and trimethylammonium-DPH (TMA-DPH) were 
obtained from Molecular Probes, Inc. 
Membrane preparation 
Synaptosomal membranes were obtained from brain cor- 
tices of male Sprague-Dawley rats as described previously 
(Cahill and Medzihradsky, 1976; Lazar and Medzihradsky, 
1992). The isolated membranes were suspended in 50 m M  
Tris-HC1 (pH 7.4) at a concentration of 3 mg of protein/ml 
and stored at -80°C until use. After solubilization with 1 M 
NaOH for 30 rnin at 25"C, membrane protein was quanti- 
fied according to the procedure of Lowry et al. (1 95 l), using 
bovine serum albumin as the standard. 
Membrane modification with CHS and OA 
CHS (0.25-2 pmol/mg of membrane protein) or OA 
(0.155-0.7 pmollmg of protein) was added as a solution in 
ethanol to membranes ( 1  mg of protein/ml) suspended in 
50 mM Tris-HC1 (pH 7.4) with vigorous mixing. Control 
membranes were incubated with a corresponding volume of 
ethanol. After incubation for 30 rnin at 25"C, the mixture 
was centrifuged for 15 rnin at 22,500 g, and the resultant 
pellet was resuspended in the Tris buffer using a Dounce 
homogenizer. 
Measurement of membrane microviscosity 
The fluorescent probe DPH or its cationic derivative 
TMA-DPH was incubated at 25°C with membranes (50 pg 
of protein) at a ratio of membrane phospholipid/probe of 
200: 1 ,  and fluorescence polarization was measured at exci- 
tation and emission wavelengths of 340 and 450 nm, respec- 
tively, as described (Lazar and Medzihradsky, 1992). The 
results were expressed as anisotropy values (r) ,  where r = (I ,  
- Zvo)/(I0 - 2Z90), and to and Z90 represent the intensities of 
light with polarizers in a parallel or perpendicular orienta- 
tion, respectively. 
Ligand binding 
Equilibrium binding of ['Hletorphine, [3H]naltrexone, 
[3H]DAMG0, and ['H]sufentanil was determined in princi- 
ple as previously described (Fischel and Medzihradsky, 
1981). In brief, assay tubes containing 150-200 pg of 
membrane protein were exposed to 5 pLM guanosine 5'-(y- 
thio)triphosphate (GTP-y-S) in the absence or presence of 
150 mM NaCl for 15 rnin at 25°C. Subsequently, the sam- 
ples were incubated with the opioids at 25°C to attain equi- 
librium in binding (30-80 min). Specific binding of the ra- 
diolabeled ligand was determined in the absence and pres- 
ence of an excess ( 1  p k l )  of the appropriate unlabeled 
ligand. Binding of the radioligands to 6 receptors was 
blocked by 50 nM oxymorphindole (Remmers and Med- 
zihradsky, 199 1 a). Reflecting the low density of K receptors 
in the membrane preparation used (Remmers and Med- 
zihradsky, 1991a), the K-selective opioid U69,593 had no 
effect on the binding of the tritiated ligands. Interference by 
K-receptor subtypes to which U69,593 does not bind was 
unlikely, because of the potent effects of low concentrations 
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FIG. 1. Microviscosity of lipid-modified membranes. Synapto- 
soma1 membranes from rat brain cortex were incubated with in- 
creasing concentrations of CHS or with 2 gmol of CHS/mg of 
membrane protein followed by increasing concentrations of OA 
(inset). After the incorporation of DPH (0) or TMA-DPH (A), fluo- 
rescence anisotropy ( r )  was determined as described in Materials 
and Methods. Data are mean f SEM (bars) values of three experi- 
ments, each carried out in duplicate. 
NEM inactivation of opioid binding 
Membranes, suspended in 50 pM Tris HCI (pH 7.4) at a 
concentration of 1 mg of protein/ml, were preincubated 
with 5 pM GTP-y-S in the absence or presence of 150 m M  
NaCl for 15 rnin at 25°C. Subsequently, the membrane sus- 
pension was incubated with 3 mM NEM for various inter- 
vals, after which receptor inactivation was terminated by 
addition of 10 mM dithiothreitol. The membranes were 
then centrifuged for 15 rnin at 22,500 g and washed with 
10-fold the original volume of ice-cold buffer. The washed 
pellet was resuspended in 50 m M  Tris-HC1 (pH 7.4) at a 
protein concentration of 1 mg of protein/ml. Residual p- 
opioid receptor binding was assayed with 0.5 nM [3H]- 
naltrexone at 25°C in the presence of I50 mMNaC1 and 50 
nM oxymorphindole. 
RESULTS 
As shown by the fluorescence anisotropy of the 
membrane probes DPH and TMA-DPH, the addition 
of CHS increased the microviscosity of both the core 
and surface regions of brain membrane (Fig. 1). 
Whereas the increase in DPH anisotropy over that in 
control membranes was statistically significant (un- 
paired Student's t test by p < 0.05) at all concentra- 
tions of CHS added (0.25-2 pmol/mg of membrane 
protein), the rise in TMA-DPH anisotropy became 
significant at a concentration of 1 pmol of CHS/mg of 
membrane protein. The microviscosity of control and 
modified membranes was unaffected by the absence 
or presence of 150 mM NaCl (data not shown). In- 
creasing concentrations of OA added to membranes 
previously rigidified by CHS progressively restored 
the microviscosity toward the level in unmodified 
membranes (Fig. 1, inset). In addition, increasing the 
temperature of control and CHS-treated membranes 
from 25 to 37°C substantially decreased the microvis- 
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FIG. 2. Effect of temperature on membrane microviscosity. Un- 
treated synaptosomal membranes (0) and membranes modified 
by addition of 2 Fmol of CHS/mg of membrane protein (0) were 
incubated with fluorescent probes as described in Materials and 
Methods. After the incorporation of DPH (A) or TMA-DPH (B), 
fluorescence anisotropy was determined at temperatures ranging 
from 25 to 37°C. At 25"C, the DPH and TMA-DPH anisotropy 
values were 0.249 and 0.287, respectively. Data are mean f SEM 
(bars) values of three experiments, each carried out in duplicate. 
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cosity of the core and surface regions of the mem- 
brane (Fig. 2). 
To avoid differential effects of membrane modifica- 
tion on free and G protein-coupled opioid receptors 
and to allow a direct comparison of agonist and antag- 
onist binding, GTP-7-S was used to uncouple the re- 
ceptor (Remmers and Medzihradsky, 199 lb); the va- 
lidity of this approach was evaluated in previous stud- 
ies on lipid modulation of opioid receptor binding 
(Remmers et al., 1990; Lazar and Medzihradsky, 
1992). Furthermore, all binding assays were carried 
out in the presence of the potent &selective opioid 
oxymorphindole to block radioligand interaction 
with the 6 receptor. Under such conditions, in control 
membranes 150 mM NaCl reduced the specific bind- 
ing of 0.5 nM ['Hletorphine by 53% and increased 
that of 0.5 nM ['Hlnaltrexone by 54% (Fig. 3). The 
concentration of 150 mMNaCl was selected consider- 
ing its widespread use to discriminate between the 
binding of opioid agonists and antagonists in brain 
membranes. However, in the present work, NaCl 
modulated ligand binding in both control and lipid- 
modified membranes with an EC,, of 6 mM, exhibit- 
ing a maximal effect at 25 mM (data not shown). 
In membranes treated with CHS the resolution by 
sodium of agonist and antagonist binding was 
strongly diminished: At the highest concentration of 
CHS examined (2 pmollmg of membrane protein), 
modulation of ['Hletorphine binding was abolished, 
whereas the enhancement of [3H]naltrexone binding 
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was limited to 10%. In contrast, in the absence of so- 
dium, CHS produced a pattern described earlier (La- 
zar and Medzihradsky, 1992): Both agonist and antag- 
onist binding was elevated (Fig. 3, inset). The decision 
to use primarily ['Hletorphine as a p ligand was based 
on two considerations: (a) Compared with the p-selec- 
tive opioid DAMGO, the binding of etorphine exhib- 
ited stronger responses to sodium (Clark et al., 1988), 
and (b) binding of ['Hletorphine was originally used 
to demonstrate the protection by sodium of receptor 
inactivation by NEM (Simon and Groth, 1975). How- 
ever, membrane modification by CHS also sup- 
pressed the sodium effect on receptor binding of the p 
agonists ['HIDAMGO (by 42.8%) and ['Hlsufentanil 
(by 37.4%). Whereas in control membranes sodium 
inhibited the binding of 2 nM [3H]DAMG0 by 77.0% 
and of 0.5 nM ['Hlsufentanil by 66.3%, in mem- 
branes modified by CHS (2 pmol/mg of membrane 
protein) the inhibition by sodium was reduced to 44.0 
and 41.5%, respectively. 
Addition of OA to membranes previously modified 
with CHS completely restored the enhancement by 
sodium of antagonist binding (Fig. 4). At a concentra- 
tion of 0.5 pmol of OA/mg of membrane protein, the 
increase was >SO%, after having been reduced to 10% 
in the corresponding CHS-treated membranes. As ob- 
served previously (Remmers et al., 1990), increasing 
concentrations of OA, in the absence or presence of 
sodium, inhibited the binding of both opioid agonists 
and antagonists (Fig. 4, inset). In addition to the fluid- 
izing effect (Fig. 2), elevation of temperature from 25 
to 37°C completely restored sodium modulation of 
antagonist binding in membranes previously rigidi- 
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FIG. 4. Reversal by OA of the sodium effect on opioid binding in 
CHS-modified membranes. Membranes treated with 2 pmol of 
CHS/mg of protein (+ +) were subsequently modified by addition 
of increasing concentrations (per milligram of membrane protein) 
of OA:0.15(+),0.3(++), 0.5(+++),and0.7(++++)pmol.The 
specific binding of 0.5 nM [3H]naltrexone in control and CHS (2 
pmol/mg of protein)- and OA-modified membranes was then de- 
termined in the absence (0) and presence (m) of 150 mM NaCl and 
in the presence of 50 nM oxymorphindole and 5 pM GTP-7-S 
(inset). Plotted is the enhancement of ligand binding by sodium 
relative to binding determined in its absence (68.7 * 3.9 fmol/mg 
of membrane protein). Data are mean k SEM (bars) values of 
three experiments, each carried out in duplicate. 
fied by CHS incorporation (Fig. 5). In contrast, so- 
dium enhancement of [3H]naltrexone binding in un- 
treated membranes was unaffected by the increase in 
temperature. 
Incubation of untreated membranes with NEM 
caused a progressive inhibition of [3H]naltrexone 
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FIG. 5. Reversal by increased temperature of the sodium effect 
on opioid binding in CHS-modified membranes. Specific binding 
of 0.5 nM [3H]naltrexone was determined at temperatures rang- 
ing from 25 to 37°C in the absence (inset) and presence of 150 
mM NaCl in untreated synaptosomal membranes (0) and mem- 
branes modified by addition of 2 pmol of CHS/mg of membrane 
protein (0). The binding assays were performed in the presence 
of 50 nM oxymorphindole and 5 pM GTP-y-S. Plotted is the en- 
hancement of ligand binding by sodium relative to binding deter- 
mined in its absence (67.5 f 4.4 fmol/mg of membrane protein). 
Data are mean c SEM (bars) values of three experiments, each 
carried out in duplicate. 
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FIG. 6. Inactivation by NEM of opioid binding in control and modi- 
fied membranes. After pretreatment with 0 (-), 1 (+), or 2 (++) 
wmol of CHS and with 0 (-) or 0.2 wmol of OA/mg of membrane 
protein (+), brain membranes were incubated with 3 mM NEM for 
various intervals in the absence (0) or presence (w) of 150 mM 
NaCI. Subsequently, binding of 0.5 nM [3H]naRrexone in the pres- 
ence of 150 mM NaCI, 50 nM oxymorphindole, and 5 pM GTP-y-S 
was determined. Plotted is the effect of Na+ on the t,,20f receptor 
inactivation determined by ligand binding; the numbers above the 
columns represent the t,,2 values in the presence/absence of so- 
dium. Data are mean & SEM (bars) values of three experiments, 
each carried out in duplicate. Inset: Time-dependent inactivation 
of receptor by NEM in untreated membranes, observed in a repre- 
sentative experiment. In the control membranes, subjected to a 
"sham" procedure of NEM inactivation, the extent of [3H]- 
naltrexone binding in the presence of sodium was 72.9 fmol/mg 
of membrane protein. 
binding to the y receptor, whereby receptor inactiva- 
tion followed pseudo-first-order kinetics (Fig. 6, in- 
set). In these membranes, sodium potently attenuated 
the rate of receptor inactivation, increasing the tl ,2 by 
185% (Fig. 6). In contrast, in membranes rigidified by 
CHS the enhancement of the t l ,2 by sodium was lim- 
ited to 42%. Subsequent addition of OA to the CHS- 
modified membranes restored sodium protection to 
80% of that observed in untreated, control mem- 
branes (Fig. 6). 
DISCUSSION 
Disruption of membrane order can significantly af- 
fect the conformation of integral membrane proteins. 
For example, fluidization of rat brain membranes by 
ethanol, fatty acid, or elevation of temperature stabi- 
lized the conformation of Na+,K+-ATPase that ex- 
hibits high affinity for ATP over that tightly binding 
K+ (Swann, 1984), whereas an increase in membrane 
lipid order due to either cholesterol incorporation or a 
decrease in temperature favored the formation of the 
meta I over the meta I1 conformation of bovine rho- 
dopsin (Mitchell et al., 1990). 
Based on the strong modulation of ligand binding 
to opioid receptors in fluidized and rigidified mem- 
branes (Remmers et al., 1990; Lazar and Med- 
zihradsky, 1992), it was postulated that the sodium- 
induced transition between the agonist- and antago- 
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nist-favoring states of opioid receptor will be affected 
by modified membrane microviscosity. In mem- 
branes rigidified by CHS, the more effective packing 
of phospholipids in the bilayer reduces the “free vol- 
ume” available for occupation by an integral mem- 
brane protein. Therefore, conformational changes of 
receptor requiring transient or stable expansion of the 
protein’s structure may be inhibited by the increased 
order of the membrane bilayer (Yeagle, 199 1). In such 
a manner, rigidification of the synaptosomal mem- 
branes by CHS could resist the sodium-induced shift 
of the opioid receptor from the “agonist” to the “an- 
tagonist” conformation proposed earlier (Pasternak 
and Snyder, 1975; Simon and Groth, 1975). If this 
were the case, subsequent fluidization of the mem- 
brane would be expected to restore the efficacy of so- 
dium displayed in the unmodified membranes. Con- 
sistent with this hypothesis, raising the temperature 
from 10 to 37”C, a process shown to decrease mem- 
brane microviscosity (Fig. 2), progressively increased 
the effect of sodium on [3H]etorphine binding to 
opioid receptors in rat brain membranes (Hitzemann 
et al., 1985). The strong and differential sensitivity of 
opioid agonist and antagonist binding to temperature 
has been reported earlier (Creese et al., 1975). 
Indeed, the results of the present study support the 
considerations outlined above. NaCl by itself had no 
effect on membrane microviscosity, but incorpora- 
tion of CHS rigidified both “core” and “surface” re- 
gions of the membrane. In these membranes the po- 
tent modulation by sodium of the binding to p recep- 
tor of both alkaloid and peptide opioid agonists as 
well as alkaloid antagonists, seen in control mem- 
branes, was abolished or strongly reduced. In addi- 
tion, CHS incorporation decreased the ability of so- 
dium to protect the receptor against inactivation by 
NEM. These results are consistent with a restriction of 
the sodium-induced transition of receptor states in 
the rigidified membranes as compared with the con- 
version between these “agonist” and “antagonist” 
states occurring in control membranes. The involve- 
ment of membrane microviscosity in the latter pro- 
cess was strongly supported by restoration of the so- 
dium effect on ligand binding and on receptor protec- 
tion following fluidization of the CHS-treated 
membranes with OA. The potent effects of this cis- 
unsaturated fatty acid on membrane microviscosity 
have previously been described (Remmers et al., 
1990; Lazar and Medzihradsky, 1992). 
A role of modulation through altered membrane 
microviscosity was also indicated by the complete res- 
toration of sodium enhancement of [3H]naltrexone 
binding in CHS-treated membranes that were subse- 
quently fluidized by temperature elevation. The in- 
ability of increasing temperature to enhance sodium 
modulation of antagonist binding in control mem- 
branes could indicate a threshold level of membrane 
microviscosity below which transition between the 
two states of p-opioid receptor is completely sup- 
ported. 
Notwithstanding the implication of membrane mi- 
croviscosity, the results of this study do not rule out a 
direct interaction of the added lipids with opioid re- 
ceptor, as described for CHS and membrane proteins 
such as glycophorin (Yeagle, 1991) or the nicotinic 
acetylcholine receptor (Fong and McNamee, 1987). It 
should also be noted that, as described for tempera- 
ture (Treistman et al., 1987), the effect of membrane 
modifications on the biophysical state of a particular 
lipid domain may be different from that observed in 
bulk membranes. Clearly, the molecular phenomena 
underlying the observed potent effects of sodium in 
modulating opioid binding will require additional re- 
search, particularly focusing on the site of ion action 
and on the role of sulkydryl groups postulated at the 
binding domain of the p receptor (Ofri and Simon, 
1992) and shown to be part of the recently disclosed 
sequence of a 6-opioid receptor (Evans et al., 1992; 
Kieffer et al., 1992). On the other hand, the data of 
this study strongly support a role of the membrane 
microenvironment, involving its microviscosity, in 
the mechanism by which sodium modulates the tran- 
sition between the agonist- and antagonist-favoring 
states of opioid receptor. The physiological signifi- 
cance of the findings is supported by the manifold 
conditions, such as development, aging, diet, and dis- 
ease, that modulate the lipid composition and fluidity 
of cell membranes (Lazar and Medzihradsky, 1992). 
It is of interest to note that in the present study low 
concentrations of NaC1, approximating intracellular 
levels, were able to modulate the conversion between 
the two states of p receptor. An intracellular site of 
sodium action in regulating opioid receptor binding 
has previously been suggested (Puttfarcken et al., 
1986). 
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